Life Science Investing Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635
Life Science Investing Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Novartis
Life Science Investing Arrowhead Pharmaceuticals Files CTA for Investigational ARO-DIMER-PA - the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia
Life Science Investing Arrowhead Pharmaceuticals Requests Regulatory Clearance to Initiate Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer's Disease and Other Tauopathies
